Also known as: messenger ribonucleic acid (mRNA) vaccine
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging the company's newly approved mNEXSPIKE vaccine uses proprietary mRNA technology without authorization.
A study of 434 toddlers found no association between maternal mRNA COVID-19 vaccination during or shortly before pregnancy and autism or other neurodevelopmental disorders in offspring aged 18-30 months.
